Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.
Myxoid chondrosarcoma is a slow-growing sarcoma poorly responsive to chemotherapy and radiation therapy. Translational research has validated several proteins as optional therapeutic targets. Significant responses are, however, rare. In this paper we report an extraordinary response of myxoid chondrosarcoma to targeted therapy by rapamycin in combination with cyclophosphamide. Our case points to a possible novel therapeutic approach towards myxoid chondrosarcoma, by targeting the mammalian target of rapamycin protein, and probably protein kinase C-alpha, mitogen-activated protein kinase, and Jun N-terminal kinase too, by rapamycin.
Merimsky
Ofer
O
Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. merimsky@zahav.net.il
Bernstein-Molho
Rinat
R
Sagi-Eisenberg
Ronit
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002813:Chondrosarcoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D011494:Protein Kinases / Q000502:physiology*; D020123:Sirolimus / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases
D003520:Cyclophosphamide; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus